BR112014001634A2 - compostos bicíclicos de pirimidona - Google Patents

compostos bicíclicos de pirimidona

Info

Publication number
BR112014001634A2
BR112014001634A2 BR112014001634A BR112014001634A BR112014001634A2 BR 112014001634 A2 BR112014001634 A2 BR 112014001634A2 BR 112014001634 A BR112014001634 A BR 112014001634A BR 112014001634 A BR112014001634 A BR 112014001634A BR 112014001634 A2 BR112014001634 A2 BR 112014001634A2
Authority
BR
Brazil
Prior art keywords
pyrimidone compounds
bicyclic pyrimidone
bicyclic
compounds
pla2
Prior art date
Application number
BR112014001634A
Other languages
English (en)
Portuguese (pt)
Inventor
Yu Haihua
Long Kai
Zhang Xiaomin
Wan Zehong
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112014001634A2 publication Critical patent/BR112014001634A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112014001634A 2011-07-27 2012-07-25 compostos bicíclicos de pirimidona BR112014001634A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011077702 2011-07-27
PCT/EP2012/064598 WO2013014185A1 (en) 2011-07-27 2012-07-25 Bicyclic pyrimidone compounds

Publications (1)

Publication Number Publication Date
BR112014001634A2 true BR112014001634A2 (pt) 2017-02-14

Family

ID=46579034

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001634A BR112014001634A2 (pt) 2011-07-27 2012-07-25 compostos bicíclicos de pirimidona

Country Status (12)

Country Link
US (2) US9273054B2 (enExample)
EP (1) EP2736908A1 (enExample)
JP (1) JP2014521625A (enExample)
KR (1) KR20140059204A (enExample)
AR (1) AR087309A1 (enExample)
AU (1) AU2012288865B2 (enExample)
BR (1) BR112014001634A2 (enExample)
CA (1) CA2843102A1 (enExample)
RU (1) RU2014107486A (enExample)
TW (1) TW201321382A (enExample)
UY (1) UY34216A (enExample)
WO (1) WO2013014185A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012288865B2 (en) * 2011-07-27 2015-10-01 Glaxo Group Limited Bicyclic pyrimidone compounds
EP2925732A1 (en) 2012-11-27 2015-10-07 Basf Se Substituted [1,2,4]triazole compounds
CN105008336A (zh) 2012-11-27 2015-10-28 巴斯夫欧洲公司 取代2-[苯氧基苯基]-1-[1,2,4]三唑-1-基乙醇化合物及其作为杀真菌剂的用途
US20160029630A1 (en) 2012-11-27 2016-02-04 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
JP2016505053A (ja) * 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
CN104968665A (zh) * 2013-01-25 2015-10-07 葛兰素史密斯克莱知识产权发展有限公司 作为lp-pla2抑制剂的双环嘧啶酮化合物
EP2948457A4 (en) * 2013-01-25 2016-09-07 Glaxosmithkline Ip Dev Ltd COMPOUNDS
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
ES2744339T3 (es) * 2014-07-22 2020-02-24 Glaxosmithkline Ip Dev Ltd Compuestos
CN105777653A (zh) 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
US20190092789A1 (en) * 2015-09-04 2019-03-28 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
CN111868055B (zh) 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
BR112022008786A2 (pt) 2019-11-09 2022-07-26 Shanghai Simr Biotechnology Co Ltd Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
EP4151638A4 (en) * 2020-05-13 2024-06-12 Neusco Biotech Limited BRIDGED CYCLIC PYRIMIDINONE COMPOUND, METHOD FOR PREPARING IT, COMPOSITION CONTAINING IT AND ITS USE
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
FI972584L (fi) 1994-12-22 1997-08-19 Smithkline Beecham Plc Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
WO1997002242A1 (en) 1995-07-01 1997-01-23 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
WO1997012963A2 (en) 1995-09-29 1997-04-10 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
CA2252696A1 (en) 1996-04-26 1997-11-06 Deirdre Mary Bernadette Hickey Azetidinone derivatives for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (en) 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
ATE283845T1 (de) 1999-05-01 2004-12-15 Smithkline Beecham Plc Pyrimidinon verbindungen
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
NZ520752A (en) 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
EP2083625A4 (en) 2006-10-13 2011-10-19 Glaxo Group Ltd BICYCLIC HETOROAROMATIC COMPOUNDS
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
ES2548878T3 (es) 2007-05-11 2015-10-21 The Trustees Of The University Of Pennsylvania Métodos de tratamiento de úlceras de la piel
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
AU2012288865B2 (en) * 2011-07-27 2015-10-01 Glaxo Group Limited Bicyclic pyrimidone compounds

Also Published As

Publication number Publication date
CA2843102A1 (en) 2013-01-31
JP2014521625A (ja) 2014-08-28
AR087309A1 (es) 2014-03-12
EP2736908A1 (en) 2014-06-04
US9273054B2 (en) 2016-03-01
US20140179716A1 (en) 2014-06-26
TW201321382A (zh) 2013-06-01
AU2012288865B2 (en) 2015-10-01
WO2013014185A1 (en) 2013-01-31
UY34216A (es) 2013-02-28
AU2012288865A1 (en) 2014-02-13
KR20140059204A (ko) 2014-05-15
RU2014107486A (ru) 2015-09-10
US20130030012A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
BR112014001634A2 (pt) compostos bicíclicos de pirimidona
UY33766A (es) COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
DOP2016000195A (es) Compuestos
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112018001303A2 (pt) ?compostos?
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
CL2017002650A1 (es) Compuestos novedosos
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
BR112014026703A2 (pt) inibidores de dna-pk
BR112014026952A8 (pt) derivados de aminopirimidina pirazol, seus usos, e composição
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
CO2017004465A2 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112013025001A2 (pt) derivados de pirazolo pirimidina
BR112015017397A2 (pt) compostos pirimidona bicíclica como inibidores de lp-pla2
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)